IP Library › Granted Patent US 12,583,873
Granted Patent B2
US 12,583,873 · App. 17/262,149 · Granted Mar 24, 2026

Amino acid mineral complex having immunopotentiating activity and composition for foods, pharmaceuticals, or feeds comprising same

Inventor: Byoung Ryol Lee (Chungcheongnam-do, KR)
Assignee: BTN CO., LTD.
C07F3/06A23K20/142A23K20/24A23K50/30A23L33/175A23L33/29A61K31/198A61K33/30A61K39/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,583,873
App. No.
17/262,149
Granted
Mar 24, 2026
Kind
B2
Abstract

The present invention relates to an amino acid mineral complex having immunopotentiating activity, and a composition for foods, pharmaceuticals, or feeds comprising the same. More particularly, the present invention relates to a composition for foods (or a food additive), pharmaceuticals, or feeds (or a feed additive) which comprises the amino acid mineral complex as an active ingredient so that it is possible to enhance the immunity of a human or an animal other than a human or increase the antibody production rate of an anti-virus vaccine.

Claims (9)

1 . A method of increasing antibody titer against foot-and-mouth disease or decreasing avian influenza virus titer in an animal in need thereof, comprising administering to the animal in need thereof an effective amount of an amino acid-mineral complex as an active ingredient, wherein the amino acid-mineral complex is a water-soluble zinc aspartate hydrate of Chemical Formula 1 having a molecular formula C 4 H 9 NO 7 Zn:

wherein the avian influenza is H1N1;

wherein the amino acid-mineral complex is comprised in a feed additive composition at a concentration between 0.1 wt % to 0.3 wt %; or

the animal in need thereof is administered 20 μg/kg/day of the amino acid-mineral complex.

2 . The method according to claim 1 , wherein the amino acid-mineral complex is comprised in a food composition, a food additive composition, a pharmaceutical composition, a feed composition or a feed additive composition.

3 . The method according to claim 1 , comprising increasing antibody titer against foot-and-mouth disease.

4 . The method according to claim 1 , comprising decreasing avian influenza virus titer.

5 . The method according to claim 3 , wherein the amino acid-mineral complex is comprised in a feed additive composition at a concentration between 0.1 wt % to 0.3 wt %.

6 . The method according to claim 4 , comprising administering to the animal in need thereof 20 μg/kg/day of the amino acid-mineral complex.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2021
From: LEE, BYOUNG RYOL
To: BTN CO., LTD.
Reel/Frame 057066/0464 →
Priority Claims (1)
KR 10-2018-0086355 · Jul 25, 2018 · national
Continuity (1)
Related Publication 20210347788A1 · Nov 11, 2021
References Cited (26)
US 3899521A · Evers · 1975 [cited by applicant]
US 4020158A · Ashmead · 1977 [cited by applicant]
US 4167564A · Jensen · 1979 [cited by applicant]
US 4216143A · Ashmead · 1980 [cited by applicant]
US 4599152A · Ashmead · 1986 [cited by applicant]
US 4721644A · Mayo · 1988 [cited by applicant]
US 4725427A · Ashmead · 1988 [cited by applicant]
US 4774089A · Ashmead · 1988 [cited by applicant]
US 4830716A · Ashmead · 1989 [cited by applicant]
US 4863898A · Ashmead · 1989 [cited by applicant]
US 6166071A · Ashmead · 2000 [cited by applicant]
US 7375243B2 · Park · 2008 [cited by applicant]
US 9718769B2 · Buisson · 2017 [cited by applicant]
US 20040131643A1 · Grewal · 2004 [cited by examiner]
US 20110117210A1 · Ugolkov · 2011 [cited by applicant]
US 20120277306A1 · Park · 2012 [cited by applicant]
CN 1467198 · 2004 [cited by applicant]
WO 2008007868A1 · 2008 [cited by applicant]
Massa, M. B., Dalosto, S. D., Ferreyra, M. G., Labadie, G., & Calvo, R. Vibronic Behavior and Single-Crystal EPR Spectra of Cu(II) in Copper-Doped Diaqua(I-aspartato)zinc(II) Hydrate. J. Phys. Chem. A 1999, 103, 15, 260… [cited by examiner]
Schubert, C., Guttek, K., Grüngreiff, K. et al. Oral zinc aspartate treats experimental autoimmune encephalomyelitis. Biometals 27, 1249-1262 (2014). (Year: 2014). [cited by examiner]
Polatnick J, Bachrach HL. Effect of zinc and other chemical agents on foot-and-mouth-disease virus replication. Antimicrob Agents Chemother. May 1978; 13(5):731-4. (Year: 1978). [cited by examiner]
Yin-Murphy M, Almond JW. Picornaviruses. In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 53. Available from: https://www.ncbi.nlm.ni… [cited by examiner]
Massa et al. Vibronic Behavior and Single-Crystal EPR Spectra of Cu(II) in Copper-Doped Diaqua(laspartato)zinc(II) Hydrate. J. Phys. Chem. 1999, 103, 15, 2606-2617. (Year: 1999). [cited by examiner]
Massa, et al., “Vibronic Behavior and Single-Crystal EPR Spectra of Cu(II) in Copper-Doped Diaqua(I-aspartato)zinc(II) Hydrate” J. Phys. Chem. A 1999, 103, 15, 2606-2617. [cited by applicant]
Mariani, et al., “Effect of zinc supplementation on plasma IL-6 and MCP-1 production and NK cell function in healthy elderly: Interactive influence of 647 MT1a and −174 IL-6 polymorphic alleles”, Experimental Gerontolog… [cited by applicant]
Unknown Author, “Preparation and properties of zine amino acid,” China Academic Journal Electronic Publishing 1 House, 1994-2023; DOI:10.19500/j.cnki.0367-6358.1997.02.008. [cited by applicant]